Protalix Biotherapeutics, Inc. (PLX)
2.65
-0.01
(-0.38%)
USD |
NYAM |
Sep 16, 15:15
Protalix Biotherapeutics Market Cap : 213.51M for Sept. 16, 2026
Market Cap Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Market Cap Data
| Date | Value |
|---|---|
| September 15, 2026 | 214.32M |
| September 14, 2026 | 223.18M |
| September 11, 2026 | 212.71M |
| September 10, 2026 | 219.96M |
| September 09, 2026 | 215.13M |
| September 08, 2026 | 213.51M |
| September 04, 2026 | 215.13M |
| September 03, 2026 | 211.10M |
| September 02, 2026 | 208.68M |
| September 01, 2026 | 208.68M |
| August 31, 2026 | 207.07M |
| August 28, 2026 | 204.65M |
| August 27, 2026 | 210.29M |
| August 26, 2026 | 199.82M |
| August 25, 2026 | 193.37M |
| August 24, 2026 | 194.18M |
| August 21, 2026 | 191.76M |
| August 20, 2026 | 191.76M |
| August 19, 2026 | 189.34M |
| August 18, 2026 | 188.54M |
| August 17, 2026 | 184.51M |
| August 14, 2026 | 178.87M |
| August 13, 2026 | 190.15M |
| August 12, 2026 | 211.10M |
| August 11, 2026 | 195.79M |
| Date | Value |
|---|---|
| August 10, 2026 | 199.82M |
| August 07, 2026 | 198.21M |
| August 06, 2026 | 196.59M |
| August 05, 2026 | 196.59M |
| August 04, 2026 | 190.95M |
| August 03, 2026 | 186.93M |
| July 31, 2026 | 190.95M |
| July 30, 2026 | 182.90M |
| July 29, 2026 | 182.90M |
| July 28, 2026 | 187.73M |
| July 27, 2026 | 193.37M |
| July 24, 2026 | 190.95M |
| July 23, 2026 | 190.95M |
| July 22, 2026 | 190.95M |
| July 21, 2026 | 190.15M |
| July 20, 2026 | 194.18M |
| July 17, 2026 | 191.76M |
| July 16, 2026 | 186.12M |
| July 15, 2026 | 187.73M |
| July 14, 2026 | 186.12M |
| July 13, 2026 | 192.57M |
| July 10, 2026 | 196.59M |
| July 09, 2026 | 190.95M |
| July 08, 2026 | 191.76M |
| July 07, 2026 | 190.15M |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Altimmune, Inc. | 631.07M |
| Taysha Gene Therapies, Inc. | 1.656B |
| Humacyte, Inc. | 157.43M |
| Agenus, Inc. | 305.13M |
| Amgen, Inc. | 203.21B |
Market Cap Related Metrics
| PE Ratio | 11.67 |
| PS Ratio | 2.686 |
| PEG Ratio | 0.0564 |
| Price to Book Value | 2.990 |
| Price to Free Cash Flow | 28.24 |
| Price | 2.65 |
| Earnings Yield | 8.57% |
| PEGY Ratio | 0.0564 |
| Operating PE Ratio | 9.297 |
| Normalized PE Ratio | 11.67 |